KR102545643B1 - 도네페질 경피 전달 시스템 - Google Patents

도네페질 경피 전달 시스템 Download PDF

Info

Publication number
KR102545643B1
KR102545643B1 KR1020227018749A KR20227018749A KR102545643B1 KR 102545643 B1 KR102545643 B1 KR 102545643B1 KR 1020227018749 A KR1020227018749 A KR 1020227018749A KR 20227018749 A KR20227018749 A KR 20227018749A KR 102545643 B1 KR102545643 B1 KR 102545643B1
Authority
KR
South Korea
Prior art keywords
donepezil
weight
drug reservoir
delete delete
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227018749A
Other languages
English (en)
Korean (ko)
Other versions
KR20220082098A (ko
Inventor
은 수 이
아미트 케이. 제인
파르민데르 싱
Original Assignee
코리움, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코리움, 엘엘씨 filed Critical 코리움, 엘엘씨
Priority to KR1020237020235A priority Critical patent/KR20230097203A/ko
Publication of KR20220082098A publication Critical patent/KR20220082098A/ko
Application granted granted Critical
Publication of KR102545643B1 publication Critical patent/KR102545643B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/0016—Plasticisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227018749A 2016-07-27 2017-07-26 도네페질 경피 전달 시스템 Active KR102545643B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237020235A KR20230097203A (ko) 2016-07-27 2017-07-26 도네페질 경피 전달 시스템

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US201662367542P 2016-07-27 2016-07-27
US201662367502P 2016-07-27 2016-07-27
US62/367,542 2016-07-27
US62/367,502 2016-07-27
US201662423133P 2016-11-16 2016-11-16
US62/423,133 2016-11-16
US201762444763P 2017-01-10 2017-01-10
US201762444745P 2017-01-10 2017-01-10
US62/444,745 2017-01-10
US62/444,763 2017-01-10
US201762457794P 2017-02-10 2017-02-10
US62/457,794 2017-02-10
US201762504391P 2017-05-10 2017-05-10
US201762504408P 2017-05-10 2017-05-10
US62/504,391 2017-05-10
US62/504,408 2017-05-10
PCT/US2017/044050 WO2018022817A1 (en) 2016-07-27 2017-07-26 Donepezil transdermal delivery system
KR1020197005331A KR102406536B1 (ko) 2016-07-27 2017-07-26 도네페질 경피 전달 시스템

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197005331A Division KR102406536B1 (ko) 2016-07-27 2017-07-26 도네페질 경피 전달 시스템

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237020235A Division KR20230097203A (ko) 2016-07-27 2017-07-26 도네페질 경피 전달 시스템

Publications (2)

Publication Number Publication Date
KR20220082098A KR20220082098A (ko) 2022-06-16
KR102545643B1 true KR102545643B1 (ko) 2023-06-21

Family

ID=59523314

Family Applications (9)

Application Number Title Priority Date Filing Date
KR1020227018749A Active KR102545643B1 (ko) 2016-07-27 2017-07-26 도네페질 경피 전달 시스템
KR1020197005331A Active KR102406536B1 (ko) 2016-07-27 2017-07-26 도네페질 경피 전달 시스템
KR1020237023326A Withdrawn KR20230109782A (ko) 2016-07-27 2017-07-26 아민 약물의 나트륨 바이카보네이트 제자리 전환 구동된경피성 전달
KR1020237020235A Ceased KR20230097203A (ko) 2016-07-27 2017-07-26 도네페질 경피 전달 시스템
KR1020227018732A Active KR102545649B1 (ko) 2016-07-27 2017-07-26 염 약물의 염 약물에서 중성 약물으로의 제자리 전환에 의한 저용해도 또는 불안정한 이온화되지 않은 중성 약물의 경피성 제제 및 전달 방법
KR1020197005739A Active KR102406528B1 (ko) 2016-07-27 2017-07-26 아민 약물의 나트륨 바이카보네이트 제자리 전환 구동된 경피성 전달
KR1020237020230A Ceased KR20230098349A (ko) 2016-07-27 2017-07-26 염 약물의 염 약물에서 중성 약물으로의 제자리 전환에 의한 저용해도 또는 불안정한 이온화되지 않은 중성 약물의 경피성 제제 및 전달 방법
KR1020227018748A Active KR102555208B1 (ko) 2016-07-27 2017-07-26 아민 약물의 나트륨 바이카보네이트 제자리 전환 구동된 경피성 전달
KR1020197005737A Active KR102406482B1 (ko) 2016-07-27 2017-07-26 염 약물의 염 약물에서 중성 약물으로의 제자리 전환에 의한 저용해도 또는 불안정한 이온화되지 않은 중성 약물의 경피성 제제 및 전달 방법

Family Applications After (8)

Application Number Title Priority Date Filing Date
KR1020197005331A Active KR102406536B1 (ko) 2016-07-27 2017-07-26 도네페질 경피 전달 시스템
KR1020237023326A Withdrawn KR20230109782A (ko) 2016-07-27 2017-07-26 아민 약물의 나트륨 바이카보네이트 제자리 전환 구동된경피성 전달
KR1020237020235A Ceased KR20230097203A (ko) 2016-07-27 2017-07-26 도네페질 경피 전달 시스템
KR1020227018732A Active KR102545649B1 (ko) 2016-07-27 2017-07-26 염 약물의 염 약물에서 중성 약물으로의 제자리 전환에 의한 저용해도 또는 불안정한 이온화되지 않은 중성 약물의 경피성 제제 및 전달 방법
KR1020197005739A Active KR102406528B1 (ko) 2016-07-27 2017-07-26 아민 약물의 나트륨 바이카보네이트 제자리 전환 구동된 경피성 전달
KR1020237020230A Ceased KR20230098349A (ko) 2016-07-27 2017-07-26 염 약물의 염 약물에서 중성 약물으로의 제자리 전환에 의한 저용해도 또는 불안정한 이온화되지 않은 중성 약물의 경피성 제제 및 전달 방법
KR1020227018748A Active KR102555208B1 (ko) 2016-07-27 2017-07-26 아민 약물의 나트륨 바이카보네이트 제자리 전환 구동된 경피성 전달
KR1020197005737A Active KR102406482B1 (ko) 2016-07-27 2017-07-26 염 약물의 염 약물에서 중성 약물으로의 제자리 전환에 의한 저용해도 또는 불안정한 이온화되지 않은 중성 약물의 경피성 제제 및 전달 방법

Country Status (10)

Country Link
US (13) US9993466B2 (enExample)
EP (3) EP3490558A1 (enExample)
JP (6) JP7071330B2 (enExample)
KR (9) KR102545643B1 (enExample)
CN (5) CN109789133A (enExample)
AU (7) AU2017302306A1 (enExample)
CA (2) CA3032044C (enExample)
MX (2) MX394249B (enExample)
SG (1) SG11201900692WA (enExample)
WO (3) WO2018022816A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6891118B2 (ja) 2014-12-23 2021-06-18 インテレクチュアル プロパティ アソシエイツ エルエルシーＩｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ａｓｓｏｃｉａｔｅｓ， ＬＬＣ 経皮投与のための方法及び製剤
SG11201804169QA (en) * 2015-11-18 2018-06-28 Commw Scient Ind Res Org Rice grain with thickened aleurone
CN108697655B (zh) 2015-12-30 2021-12-10 考里安公司 用于长期透皮施药的系统和方法
CN109922796B (zh) 2016-06-23 2023-04-07 考里安有限责任公司 具有亲水和疏水域的粘合剂基质和治疗剂
KR102508993B1 (ko) 2016-07-27 2023-03-10 코리움, 인크. 메만틴 경피 송달 시스템
CA3032044C (en) 2016-07-27 2024-10-01 Corium, Llc DONEPEZIL TRANSDERMAL ADMINISTRATION SYSTEM
CN111132669A (zh) * 2017-07-26 2020-05-08 考里安公司 具有带溶剂填充孔的微孔膜的透皮递送系统
WO2019055880A2 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. METHOD OF ADMINISTRATION AND TREATMENT
WO2019126531A1 (en) 2017-12-20 2019-06-27 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
KR102710072B1 (ko) * 2018-08-31 2024-09-24 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
KR102823139B1 (ko) * 2018-08-31 2025-06-19 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
KR102115102B1 (ko) 2018-12-21 2020-05-26 동아에스티 주식회사 안정화된 도네페질 함유 경피 흡수제제
KR102372630B1 (ko) * 2019-05-15 2022-03-14 주식회사 대웅제약 고함량의 도네페질 또는 그의 염을 포함하는 경피흡수제제
US11101101B2 (en) * 2019-05-15 2021-08-24 Fei Company Laser-based phase plate image contrast manipulation
CN114599349B (zh) * 2019-10-24 2024-04-09 罗曼治疗系统股份公司 用于透皮施用芬戈莫德的透皮治疗系统
JP7202450B2 (ja) * 2019-11-26 2023-01-11 久光製薬株式会社 ロピニロール含有貼付剤の粘着剤層保持力向上方法、及びロピニロール含有保持力改善貼付剤
CN114829580A (zh) * 2019-12-18 2022-07-29 先锋国际良种公司 用于提高植物籽粒产量的组合物和方法
EP4135673A4 (en) * 2020-04-14 2024-05-08 Glanis Pharmaceuticals, Inc. TRANSDERMAL AND/OR TOPICAL ADMINISTRATION SYSTEM COMPRISING HYDROXYCHLOROQUINE AND/OR CHLOROQUINE
JP2022044038A (ja) * 2020-09-04 2022-03-16 株式会社大石膏盛堂 ドネペジル含有経皮吸収液剤およびその製造方法
CN112656778A (zh) * 2020-12-28 2021-04-16 广东红珊瑚药业有限公司 一种压敏胶基质以及一种贴剂
US12270039B2 (en) * 2021-05-14 2025-04-08 Board Of Trustees Of Southern Illinois University Compositions and methods to increase oleic acid content in soybeans
US12270040B2 (en) * 2021-05-27 2025-04-08 Board Of Trustees Of Southern Illinois University Soybean lines with low saturated fatty acid and high oleic acid contents
AU2022306570A1 (en) * 2021-07-08 2024-01-18 Monsanto Technology Llc Novel insect inhibitory proteins
WO2023136966A1 (en) * 2022-01-12 2023-07-20 Inari Agriculture Technology, Inc. Reduced height maize
WO2025103446A1 (zh) * 2023-11-16 2025-05-22 宜昌人福药业有限责任公司 含有多奈哌齐的透皮贴剂及其制备方法

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
NL134681C (enExample) 1966-04-26
US3546141A (en) 1966-08-08 1970-12-08 Mc Donnell Douglas Corp Phosphorus-nitrogen polymers and process
NL7305644A (enExample) 1972-04-20 1973-10-23
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
DE3572485D1 (en) 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
US4797284A (en) * 1986-03-12 1989-01-10 Merck & Co., Inc. Transdermal drug delivery system
US4880633A (en) 1986-03-12 1989-11-14 Merck & Co., Inc. Transdermal drug delivery system
DE3634016A1 (de) 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4837027A (en) 1987-11-09 1989-06-06 Alza Corporation Transdermal drug delivery device
US4781924A (en) 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
US4849224A (en) 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US5026556A (en) 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
DE58905637D1 (de) 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
DE3913734C2 (de) * 1989-04-26 1998-08-20 Roehm Gmbh Verwendung einer wäßrigen Hauthaftkleberlösung zur Herstellung einer mit Wasser leicht abwaschbaren Klebschicht
MY115126A (en) * 1990-04-27 2003-04-30 Seikisui Chemical Co Ltd Percutaneously absorbable eperisone or tolperisone preparation.
US5252588A (en) * 1990-04-27 1993-10-12 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation
NZ239033A (en) 1990-07-23 1994-04-27 Alza Corp Semipermeable capsule with a hole containing a nicotine salt which reacts with water to release nicotine base
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5123900A (en) 1991-08-16 1992-06-23 Bertek, Inc. Moisture permeable double disk
JPH06199659A (ja) 1992-10-28 1994-07-19 Hisamitsu Pharmaceut Co Inc 経皮治療用装置
DE4310012A1 (de) * 1993-03-27 1994-09-29 Roehm Gmbh Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung
US5424077A (en) 1993-07-13 1995-06-13 Church & Dwight Co., Inc. Co-micronized bicarbonate salt compositions
DE69528165T2 (de) 1994-04-21 2003-05-15 Hisamitsu Pharmaceutical Co., Inc. Transdermal verabreichbare grundlage und daraus hergestelltes transdermal verabreichbares arzneimittel
WO1996008229A2 (en) 1994-09-14 1996-03-21 Minnesota Mining And Manufacturing Company Matrix for transdermal drug delivery
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
AU695170B2 (en) 1994-12-21 1998-08-06 Theratech, Inc. Transdermal delivery system with adhesive overlay and peel seal disc
AU6032696A (en) 1995-06-07 1996-12-30 Cygnus Therapeutic Systems Pressure sensitive acrylate adhesive composition cross-linke d with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group
DE19531342B4 (de) 1995-08-25 2007-11-29 Merz Pharma Gmbh & Co. Kgaa Verwendung von Aminoadamantan-Verbindungen als Immunregulatoren
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5958919A (en) 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
DK0934078T3 (da) 1996-10-24 2003-04-14 Alza Corp Permeabilitetsfremmere til transdermal administrering af aktivstoffer, anordninger og fremgangsmåde til fremstilling deraf
CN1174031A (zh) * 1997-04-23 1998-02-25 谢先运 双氯芬酸钠透皮控释贴膏
US5866585A (en) 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US20040018241A1 (en) * 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6193993B1 (en) 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
JP4205778B2 (ja) * 1998-04-17 2009-01-07 久光製薬株式会社 貼付製剤
DE19820999A1 (de) 1998-05-11 1999-11-18 Lohmann Therapie Syst Lts Laminat zum Aufbringen auf einen Akzeptor
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20020192243A1 (en) * 1999-12-16 2002-12-19 Tsung-Min Hsu Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
CN100340237C (zh) * 2000-11-06 2007-10-03 株式会社三养社 吸水性和粘附性能改善的经皮给药系统
CA2428181A1 (en) * 2000-11-07 2002-05-16 Hisamitsu Pharmaceutical Co., Inc. Pharmaceutical preparation of percutaneous absorption type
JP4850346B2 (ja) * 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
US8728445B2 (en) 2001-05-01 2014-05-20 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences Hydrogel Compositions
EP1427404A4 (en) 2001-08-20 2005-10-26 Maiken Nedergaard TREATMENT OF GLIAL TUMORS WITH GLUTAMATE ANTAGONISTS
EP1423100B1 (en) 2001-09-04 2007-01-24 Trommsdorff GmbH & Co.KG Arzneimittel Plaster comprising sertaconazole for the treatment of dysfunctions and disorders of nails
US20040258741A1 (en) * 2001-10-17 2004-12-23 Takaaki Terahara Percutaneous absorption preparations
ITMI20012827A1 (it) * 2001-12-28 2003-06-28 Fidia Farmaceutici Formulazioni adesive transdermiche di diclofenac sodico
US7273619B2 (en) 2002-01-17 2007-09-25 Samyang Corporation Transdermal composition of an antivomiting agent
EP2260839A3 (en) 2002-10-24 2012-05-02 Merz Pharma GmbH & Co. KGaA Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
MXPA06003316A (es) 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Formulacion farmaceutica transdermica para minimizar los residuos en la piel.
WO2005037157A1 (en) * 2003-10-14 2005-04-28 Dermatrends, Inc. Enhancing transdermal administration of hydrophilic drugs
AR046601A1 (es) 2003-10-22 2005-12-14 Merz Pharma Gmbh & Co Kgaa Uso de derivados 1- aminociclohexano para modificar la deposicion de peptidos ab fibrosos en amiloidopatias
WO2005039651A2 (en) 2003-10-23 2005-05-06 Trans1 Inc. Tools and tool kits for performing minimally invasive procedures on the spine
JP2007512338A (ja) 2003-11-21 2007-05-17 メモリー・ファーマシューティカルズ・コーポレイション Ｌ型カルシウムチャンネルブロッカーとコリンエステラーゼ阻害剤を用いた組成物及び処置方法
US7176185B2 (en) 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
KR20070030178A (ko) 2004-02-17 2007-03-15 트랜스오랄 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법
US7670838B2 (en) 2004-05-24 2010-03-02 The Board Of Trustees Of The Leland Stanford Junior University Coupling of excitation and neurogenesis in neural stem/progenitor cells
US20080038328A1 (en) 2004-05-28 2008-02-14 Naruhito Higo Pasting Preparation
TW200616608A (en) 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
CA2583340C (en) 2004-10-08 2015-09-08 Noven Pharmaceuticals, Inc. Transdermal drug delivery device including an occlusive backing
EP1661560B1 (en) 2004-11-22 2008-11-05 Hisamitsu Pharmaceutical Co., Inc. Transdermal patch comprising a melting point lowering agent
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
HRP20090676T1 (hr) 2005-01-11 2010-01-31 Teva Pharmaceutical Fine Chemicals S.R.L. Postupak dobivanja 1-amino-3,5-dimetiladamantan-hidroklorida
WO2006082728A1 (ja) * 2005-02-04 2006-08-10 Hisamitsu Pharmaceutical Co., Inc. 経皮吸収貼付剤
US20060188558A1 (en) 2005-02-18 2006-08-24 Mylan Technologies, Inc. Transdermal systems having control delivery system
BRPI0607017B8 (pt) 2005-04-06 2021-05-25 Adamas Pharmaceuticals Inc composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
US7888422B2 (en) 2005-11-09 2011-02-15 Mylan Technologies Inc. Long-wearing removable pressure sensitive adhesive
US20070237916A1 (en) * 2006-03-28 2007-10-11 Torben Rasmussen Multilayer film free of halogens which is impermeable to aroma compounds
CN1895242B (zh) * 2006-04-13 2011-08-31 沈阳药科大学 双氯芬酸盐的透皮贴剂及制备方法
IL175338A0 (en) 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
MY149152A (en) 2006-05-08 2013-07-15 Teikoku Seiyaku Kk Percutaneous absorption preparations of antimentia drugs
JP5097359B2 (ja) * 2006-05-09 2012-12-12 久光製薬株式会社 ドネペジル経皮吸収型製剤
TW200815045A (en) 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
US9248104B2 (en) 2006-08-17 2016-02-02 Core Tech Solutions, Inc. Transdermal methods and systems for treating Alzheimer's disease
US20080107719A1 (en) 2006-11-08 2008-05-08 Sukhon Likitlersuang Transdermal drug delivery system
EP2098233A4 (en) 2006-12-01 2012-03-21 Nitto Denko Corp PREPARATION OF SKIN ADHESIVE COMPRISING DERESEPZIL STABILIZED
KR101408488B1 (ko) * 2006-12-01 2014-06-17 닛토덴코 가부시키가이샤 도네페질 함유 접착 제제의 경시적인 변색을 억제하는 방법
CN101605545B (zh) 2006-12-01 2011-10-05 日东电工株式会社 含有稳定化的多奈哌齐的贴剂
JP5403948B2 (ja) 2007-06-07 2014-01-29 久光製薬株式会社 メマンチン含有経皮吸収製剤
AU2008275101B2 (en) 2007-07-10 2014-08-21 Agile Therapeutics, Inc. Dermal delivery device with in situ seal
US9017301B2 (en) * 2007-09-04 2015-04-28 Mylan Technologies, Inc. Transdermal drug delivery systems comprising a coated release liner
JP2009203213A (ja) * 2008-02-28 2009-09-10 Kosumedei Seiyaku Kk 経皮吸収医薬組成物
DE102008013701A1 (de) * 2008-03-11 2009-09-17 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit stabilisierter Membran
KR101454362B1 (ko) 2008-03-24 2014-10-23 아이큐어 주식회사 도네페질을 유효성분으로 함유하는 치매 치료용경피흡수제제
EP2111857A1 (de) 2008-04-25 2009-10-28 Acino AG Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff hiervon
US20090291127A1 (en) 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
PE20100371A1 (es) 2008-10-31 2010-06-01 Lexicon Pharmaceuticals Inc Agonistas del receptor s1p para el tratamiento de malaria cerebral
US20100178037A1 (en) 2009-01-12 2010-07-15 Te-Wei Chen Display apparatus, video generation apparatus, and method thereof
WO2010083035A2 (en) * 2009-01-14 2010-07-22 Corium International, Inc. Transdermal administration of tamsulosin
KR101725832B1 (ko) 2009-05-01 2017-04-11 히사미쓰 세이야꾸 가부시키가이샤 경피 흡수형 제제
WO2011034323A2 (en) 2009-09-16 2011-03-24 Samyang Corporation Transdermal delivery system, method for manufacturing the same, and transdermal delivery method using the system
KR101734602B1 (ko) 2009-10-21 2017-05-11 데이고꾸세이약꾸가부시끼가이샤 도네페질 함유 경피 흡수형 제제
CN102048678A (zh) * 2009-10-30 2011-05-11 北京隆旗生物科技有限公司 一种奥昔布宁的透皮吸收制剂及其制备方法与药物应用
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
JP2012236773A (ja) 2009-12-16 2012-12-06 Goto Takeshi 抗認知症薬物の経皮吸収製剤
EP2519225B1 (en) 2009-12-30 2015-03-25 Novartis AG Melt extruded nicotine thin strips
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
JP5615898B2 (ja) 2010-02-24 2014-10-29 久光製薬株式会社 貼付剤
US20110244023A1 (en) * 2010-03-30 2011-10-06 Phosphagenics Limited Transdermal delivery patch
WO2011136288A1 (ja) 2010-04-28 2011-11-03 久光製薬株式会社 ドネペジル含有経皮吸収製剤
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
DE102010024105A1 (de) 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
US20140370076A1 (en) 2010-06-30 2014-12-18 Nal Pharmaceuticals, Ltd. Transdermal drug delivery system containing donepezil
NZ605352A (en) * 2010-06-30 2013-10-25 Nal Pharmaceuticals Ltd Process for producing glycosaminoglycans
AU2011282683B2 (en) 2010-07-29 2016-12-22 Allergan, Inc. Preservative free brimonidine and timolol solutions
AU2011316565A1 (en) 2010-10-12 2013-05-02 Cerecor Inc. Antitussive compositions comprising memantine
JP5699554B2 (ja) 2010-11-11 2015-04-15 富士通株式会社 ベクトル処理回路、命令発行制御方法、及びプロセッサシステム
CA2815898C (en) 2010-11-17 2018-12-18 Hexal Ag Transdermal therapeutic system comprising buprenorphine
WO2012084969A1 (en) 2010-12-22 2012-06-28 Hexal Ag Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition
EP2658576A1 (en) * 2010-12-29 2013-11-06 Pharmafilm S.R.L. Medicated patch for improved transdermal permeation of diclofenac diethylammonium
TWI433904B (zh) 2011-01-12 2014-04-11 Taiwan Biotech Co Ltd 多奈哌齊經皮貼片
CN102775476B (zh) 2011-05-12 2015-01-07 上海天伟生物制药有限公司 一种米卡芬净钠盐的制备方法
US8673338B2 (en) 2011-07-29 2014-03-18 Massachusetts Eye And Ear Infirmary Methods of delivering pharmaceutical agents
JP5808214B2 (ja) 2011-09-30 2015-11-10 株式会社トクヤマ 貼付剤
KR101239150B1 (ko) 2012-02-28 2013-03-06 에스케이케미칼주식회사 도네페질-함유 경피흡수제제 및 그의 제조방법
US9408802B1 (en) * 2012-03-22 2016-08-09 Prosolus, Inc. Seven day drug in adhesive transdermal delivery
US9145907B2 (en) 2012-08-28 2015-09-29 Hsiutao Liang Pipe connector
US20140256690A1 (en) 2013-03-08 2014-09-11 Agile Therapeutics, Inc. Contraceptive method
WO2014174564A1 (ja) 2013-04-22 2014-10-30 祐徳薬品工業株式会社 メマンチン含有経皮吸収型貼付製剤
JP5415645B1 (ja) * 2013-06-28 2014-02-12 久光製薬株式会社 貼付剤の製造方法、貼付剤及び包装体
WO2015031552A1 (en) * 2013-08-30 2015-03-05 3M Innovative Properties Company Estradiol containing transdermal drug delivery systems and compositions
KR101827980B1 (ko) 2013-10-07 2018-02-13 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
JP6401257B2 (ja) * 2013-10-11 2018-10-10 テイコク ファーマ ユーエスエー インコーポレーテッド 局所用スフィンゴシン−１−リン酸受容体アゴニスト製剤及びその使用方法
EP3069712B1 (en) 2013-11-17 2020-09-23 MEDRx Co., Ltd. Transdermal colloidal solution agent
KR101485822B1 (ko) 2014-01-22 2015-01-23 주식회사 대웅제약 도네페질 또는 그의 염을 함유하는 경피흡수제제
JP2015151370A (ja) * 2014-02-14 2015-08-24 日東電工株式会社 貼付製剤
WO2015200472A1 (en) 2014-06-24 2015-12-30 KAT Transdermals LLC Transdermal delivery system
US10071090B2 (en) * 2014-07-18 2018-09-11 Buzzz Pharmaceuticals Limited Oxymorphone transdermal patch
CN106687138B (zh) 2014-09-03 2021-10-15 日东电工株式会社 包含双膦酸盐剂的细胞性免疫用疫苗药物组合物
WO2016046675A1 (en) 2014-09-28 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of neurological diseases
WO2016099198A1 (ko) 2014-12-18 2016-06-23 아이큐어 주식회사 도네페질을 유효성분으로 함유하는 경피흡수제제
AU2015380301B2 (en) 2015-01-28 2020-04-23 Dnx Biotech, Llc Compositions and methods of using a soluble TNF-alpha receptor modified for increased half-life
US20180185298A1 (en) 2015-06-22 2018-07-05 Corium International, Inc. Transdermal Adhesive Composition Comprising A Poorly Soluble Therapeutic Agent
JP6462880B2 (ja) 2015-07-27 2019-01-30 久光製薬株式会社 アセナピン含有貼付剤の製造方法
CN108697655B (zh) * 2015-12-30 2021-12-10 考里安公司 用于长期透皮施药的系统和方法
CN105693556A (zh) 2016-03-01 2016-06-22 巴斯特医药科技（常州）有限公司 卡巴拉汀酒石酸盐的转化方法及其产物制成的贴片
CN109922796B (zh) 2016-06-23 2023-04-07 考里安有限责任公司 具有亲水和疏水域的粘合剂基质和治疗剂
CA3032044C (en) 2016-07-27 2024-10-01 Corium, Llc DONEPEZIL TRANSDERMAL ADMINISTRATION SYSTEM
KR102508993B1 (ko) 2016-07-27 2023-03-10 코리움, 인크. 메만틴 경피 송달 시스템
WO2018022814A1 (en) * 2016-07-27 2018-02-01 Corium International, Inc. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
CN111132669A (zh) 2017-07-26 2020-05-08 考里安公司 具有带溶剂填充孔的微孔膜的透皮递送系统

Also Published As

Publication number Publication date
KR20220082098A (ko) 2022-06-16
US20250375395A1 (en) 2025-12-11
CN116966166A (zh) 2023-10-31
JP2019525932A (ja) 2019-09-12
AU2023203616A1 (en) 2023-07-06
MX394249B (es) 2025-03-24
RU2019105279A (ru) 2020-08-27
EP3490558A1 (en) 2019-06-05
MX2022006681A (es) 2022-07-11
KR102406536B1 (ko) 2022-06-08
JP7071330B2 (ja) 2022-05-18
US20240156747A1 (en) 2024-05-16
WO2018022815A3 (en) 2018-03-08
JP2022093707A (ja) 2022-06-23
WO2018022817A1 (en) 2018-02-01
WO2018022815A2 (en) 2018-02-01
JP7251033B2 (ja) 2023-04-04
KR20230109782A (ko) 2023-07-20
US20180028462A1 (en) 2018-02-01
CA3031945A1 (en) 2018-02-01
KR20220082928A (ko) 2022-06-17
EP3490541B1 (en) 2025-07-09
CN109789106B (zh) 2023-06-27
KR20190032512A (ko) 2019-03-27
US20220016045A1 (en) 2022-01-20
KR20230098349A (ko) 2023-07-03
US20190247321A1 (en) 2019-08-15
US10300025B2 (en) 2019-05-28
CA3031945C (en) 2025-09-23
KR20190034601A (ko) 2019-04-02
US20180028663A1 (en) 2018-02-01
US20180028463A1 (en) 2018-02-01
MX2019001103A (es) 2019-09-27
SG11201900692WA (en) 2019-02-27
CA3032044C (en) 2024-10-01
RU2019105279A3 (enExample) 2020-12-23
CN109789105A (zh) 2019-05-21
JP2022121629A (ja) 2022-08-19
AU2023203618A1 (en) 2023-07-06
CN109789105B (zh) 2022-12-27
KR102555208B1 (ko) 2023-07-17
KR20230097203A (ko) 2023-06-30
JP2019523268A (ja) 2019-08-22
US10307379B2 (en) 2019-06-04
US9993466B2 (en) 2018-06-12
KR20190035801A (ko) 2019-04-03
EP3490540A1 (en) 2019-06-05
US11103463B2 (en) 2021-08-31
US20180028512A1 (en) 2018-02-01
CN109789106A (zh) 2019-05-21
KR102545649B1 (ko) 2023-06-22
US20190247320A1 (en) 2019-08-15
JP7153010B2 (ja) 2022-10-13
AU2023203618B2 (en) 2025-09-18
US20210015761A1 (en) 2021-01-21
KR102406528B1 (ko) 2022-06-08
EP3490541A2 (en) 2019-06-05
AU2017302307A1 (en) 2019-02-14
AU2017301928B2 (en) 2023-04-06
JP2019523270A (ja) 2019-08-22
AU2017302306A1 (en) 2019-02-14
US20250375396A1 (en) 2025-12-11
WO2018022816A1 (en) 2018-02-01
AU2025205205A1 (en) 2025-07-24
CN116270551A (zh) 2023-06-23
KR20220082929A (ko) 2022-06-17
KR102406482B1 (ko) 2022-06-08
CN109789133A (zh) 2019-05-21
US20250325496A1 (en) 2025-10-23
JP2022140751A (ja) 2022-09-27
US20180235901A1 (en) 2018-08-23
AU2023204240A1 (en) 2023-07-27
CA3032148A1 (en) 2018-02-01
AU2017301928A1 (en) 2019-02-14
CA3032044A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
KR102545643B1 (ko) 도네페질 경피 전달 시스템
US20240041791A1 (en) Transdermal adhesive composition comprising a poorly soluble therapeutic agent
JP7611327B2 (ja) 溶媒充填細孔を有する微多孔膜を有する経皮送達システム
US10945968B2 (en) Memantine transdermal delivery systems
US20240082172A1 (en) Method for depot creation during transdermal drug delivery
RU2779471C2 (ru) Трансдермальная система доставки донепезила

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601